 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- || LY4101174 / Eli Lilly
Enrollment change: A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 23, 2025
P1, N=490, Recruiting, Sponsor: Eli Lilly and Company
N=280 --> 490
- | LY4101174 / Eli Lilly
Journal: ETx-22: a novel nectin-4-directed antibody drug conjugate, demonstrates safety and potent antitumor activity in low nectin-4 expressing tumors. (Pubmed Central) - Nov 22, 2024
ETx-22 has a highest non severely toxic dose of over 20 mg/kg in non-human primates without signs of important skin toxicity. ETx-22 represents a valuable therapy, for the treatment of patients with nectin-4 expressing tumors including those that have become resistant to enfortumab vedotin treatment.
- ||| LY4101174 / Eli Lilly
Enrollment open: A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 15, 2024
P1, N=280, Recruiting, Sponsor: Eli Lilly and Company
ETx-22 represents a valuable therapy, for the treatment of patients with nectin-4 expressing tumors including those that have become resistant to enfortumab vedotin treatment. Not yet recruiting --> Recruiting
- LY4101174 / Eli Lilly
A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress) (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_3883;
Not yet recruiting --> Recruiting Abstract is embargoed at this time.
- ||| LY4101174 / Eli Lilly
New P1 trial: A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 2, 2024
P1, N=280, Not yet recruiting, Sponsor: Eli Lilly and Company
- ||| ETx-22 / Emergence Therap
Review: ETx-22https://www.adcreview.com/drugmap/etx-22-is-an-next-gen-anti-nectin-4-adc/ (Twitter) - Sep 19, 2022